Patent Term Extension Application for LIFYORLI® (relacorilant), Patent No. 8,859,774 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-8228

Patent Term Extension Application for LIFYORLI® (relacorilant), Patent No. 8,859,774

Documents

Comments

Description

OPEN

Comment Period OpensJul 30, 2026

Type	Title	Posted	Comments	Status
Other	Letter from U. S. Patent and Trademark Office to FDA CDER	Jul 30, 2026	--

CDER

Patent Term Extension Application for LIFYORLI®

Mintz, Levin, Cohn, Ferris,

Glovsky and Popeo, P.C.

Corcept Therapeutics Incorporated

(relacorilant)

Patent No. 8,859,774

OPEN